Delaware Chapter of the American College of Cardiology

Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) October 25 – 27, 2024!

For more Information and Register: Delaware ACC By the Sea: 2024 Chapter Meeting

Delaware Chapter of the American College of Cardiology

Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

Lp(a) and CV Risk; CRP Levels and High-Risk Vulnerable Plaque post-NSTEMI; Pulsed Field Ablation vs. Cryoablation for Paroxysmal AFib
In this weekâ€™s View, Dr. Eagle looks at Lp(a) levels and cardiovascular (CV) risk. He then discusses the potential value of high-sensitivity C-reactive protein (hsCRP) in identifying high-risk and more vulnerable plaque in patients after non-ST-segment elevation myocardial infarction (STEMI).
Disparities in Hypertension Across Age Spectrum Among Asian American Adults: The Power of Data Disaggregation
There is an increasing appreciation of the racial differences in cardiovascular disease (CVD) risk profiles and subsequent outcomes. This recognition has led to meaningful changes in clinical practice, such as screening for diabetes mellitus earlier...
ACCEL Lite: STRIDE Trial: Effects of Semaglutide in Patients With Peripheral Artery Disease
In this interview, Drs. Alison Bailey and Marc Bonaca discuss how the STRIDE trial data supports the use of semaglutide for individuals with PAD and type 2 diabetes, highlighting its cardiometabolic, cardiovascular, and kidney benefits, as well as its ability to improve function, symptoms, and overall quality of life.
AHA Scientific Statement Update on Kawasaki Disease: Identifying and Managing Patients at High Risk
There have been significant advances in the understanding of Kawasaki disease (KD) since the first published report in 1967. The recently published 2024 American Heart Association scientific statement reviews the latest evidence and expert consensus since the prior version in 2017...
FDA Update: Abbott Removes HeartMate Mobile Power Unit
The U.S. Food and Drug Administration (FDA) announced on April 24 that Abbott has removed the HeartMate Mobile Power Unit, used with HeartMate II and HeartMate 3 Left Ventricular Assist Systems, due to reports of sudden, unexpected power loss.